Sign In
News Digest /
Ticker:SNY
Ticker:SNY
06:45am, Friday, Jan 16, 2026
UBS downgrades Sanofi to neutral, slashing earnings forecasts after trial failures and risks to key drug Dupixent. Weak pipeline and FDA delays cloud the pharma giant's growth outlook.
04:15am, Friday, Jul 25, 2025
Sanofi's Sarclisa gains EU approval for first-line use in stem cell transplant-eligible multiple myeloma patients, expanding its market potential and enhancing treatment options. This boosts Sanofi's oncology prospects and market position in Europe.
10:03am, Monday, Jun 02, 2025
Sanofi extends its licensing agreement with Nurix Therapeutics for the STAT6 program, allowing Nurix to earn up to $465 million. This partnership signals potential long-term value creation amid a competitive biotech landscape, drawing investor attention.
04:04am, Thursday, Mar 20, 2025
Sanofi (NASDAQ: SNY) plans to acquire Dren Bio's immunology operations, focusing on autoimmune treatment DR-0201, with an initial $600 million payment and up to $1.3 billion in milestones. Completion is expected by Q2 2025, posing potential stock volatility for investors.
08:17am, Friday, May 10, 2024
Dow, S&P 500, and Nasdaq gain on economic optimism. Gold prices rebound, while Novavax secures a pivotal deal with Sanofi. Oil prices also rise.
